STD Tests: 2026 AI Market Discovery Index

Answer Capsule

In the STD testing category for August 2026, AI platforms are consolidating buyer choice around a small set of at-home testing brands. Everlywell leads with the strongest recommendation coverage and the highest rank-one rate in the category. myLAB Box and LetsGetChecked form the closest challenger tier. Nurx and Labcorp OnDemand show meaningful presence but weak recommendation conversion. STDcheck.com is entirely absent from AI-driven discovery across all six platforms.

For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending STD Tests

Executive Summary

AI platforms are now functioning as the primary shortlist builder for STD testing decisions, and the August 2026 benchmark shows a clear concentration of recommendation power around three brands. Everlywell leads with a 37.2% valid recommendation coverage rate and an 11.3% rank-one rate, appearing as the top recommendation in more than one in ten AI responses. Its 62.3% net sentiment score indicates that when AI systems mention Everlywell, they frame it favorably and consistently.

myLAB Box and LetsGetChecked form the most credible challenger tier. myLAB Box achieves 33.6% recommendation coverage and a 9.97% rank-one rate, placing it in direct competition with the leader for top positions. LetsGetChecked reaches 27.9% coverage with a 5.0% rank-one rate, earning consistent shortlist placement but less frequently as the first-choice answer.

The most commercially significant pattern in this benchmark is the gap between presence and recommendation power. Labcorp OnDemand appears in 36.5% of AI responses but converts only 14.3% into valid recommendations. Nurx appears in 26.9% of responses but converts only 10.9%. These brands are known to AI systems but are not being advanced as primary choices at the moment of decision.

Recommendation credit matters because AI platforms now compress the consideration set before a buyer reaches any product page, review site, or clinic locator. Brands that earn top-three placement in AI responses capture a structurally different kind of demand than brands that merely appear in factual references. The gap between those two states is the central commercial risk this category now faces.

The AI Discovery Shift in STD Testing

Traditional search visibility assumed that appearing in results was the primary competitive battleground. AI platforms have changed this by generating a direct answer that includes a ranked shortlist, typically three to five brands, rather than a list of links to evaluate independently. Being mentioned somewhere in an AI response is no longer sufficient. Being advanced as a positive, ranked recommendation is what determines selection.

The August 2026 data shows that AI systems are discriminating sharply between brands they recognize and brands they recommend. Everlywell, myLAB Box, and LetsGetChecked consistently appear in recommendation lists across all six platforms tested. Other brands appear in factual references, neutral comparisons, or passing mentions, but rarely as the answer to a direct purchase question.

This distinction matters at scale because AI platforms build recommendation confidence through public source evidence. When a system recommends a brand for STD testing, it typically draws on review content, comparison articles, clinical or health-authority references, and official brand information. Brands with deeper source architecture across these layers are more likely to be retrieved, verified, and advanced as shortlist candidates. Brands with thinner evidence layers are recognized but not trusted enough to recommend.

Directional Category Leaders

1. Everlywell

Everlywell leads the STD testing category with the strongest overall recommendation profile across all six AI platforms. The brand appears in 78.4% of AI responses and converts 37.2% of observations into valid recommendations, both the highest figures in the category. Its rank-one rate of 11.3% and average recommended rank of 2.02 indicate that when Everlywell appears on a shortlist, it typically appears near the top. A 62.3% net sentiment score confirms that AI systems frame the brand favorably rather than neutrally.

The public interpretation: Everlywell has become the default first-choice recommendation for AI systems answering STD testing questions, and its lead is currently not under direct threat.

2. myLAB Box

myLAB Box is the strongest challenger to Everlywell, with 65.8% presence and 33.6% recommendation coverage. Its rank-one rate of 9.97% and average recommended rank of 2.08 place it in direct competition with the leader for top-position credit. myLAB Box also holds the highest net sentiment score in the category at 65.7%, suggesting that AI systems frame it more favorably than any other brand when it appears. The gap between myLAB Box and Everlywell is narrow at the top-rank level and could close with stronger source architecture.

The public interpretation: myLAB Box has converted strong brand recognition into near-leader recommendation status and is the most credible competitive threat in the category.

3. LetsGetChecked

LetsGetChecked holds third position with 61.8% presence and 27.9% recommendation coverage. Its rank-one rate drops to 5.0% and its average recommended rank of 2.38 places it slightly behind the top two, but the brand remains a consistent shortlist member across platforms. A 61.3% net sentiment score indicates positive framing when mentioned. The gap between its coverage rate and rank-one rate suggests AI systems include LetsGetChecked as a reliable option rather than a first-choice answer.

The public interpretation: LetsGetChecked is a durable shortlist presence but is currently positioned as the trusted alternative rather than the recommended leader.

4. Labcorp OnDemand

Labcorp OnDemand presents the most commercially consequential visibility gap in the benchmark. The brand appears in 36.5% of AI responses, the fourth-highest presence rate in the category, but converts only 14.3% into valid recommendations. Its rank-one rate is 1.0% and its average recommended rank of 2.73 places it lower in shortlists when it does appear. A 19.6% positive visibility rate indicates that AI systems can frame the brand favorably but do not do so consistently enough to generate recommendation credit.

The public interpretation: Labcorp OnDemand benefits from the parent brand's institutional credibility but has not translated that recognition into AI recommendation power, leaving significant demand on the table.

5. Nurx

Nurx shows a similar pattern to Labcorp OnDemand, with 26.9% presence and only 10.9% recommendation coverage. Its rank-one rate is 1.0% and its average recommended rank of 3.03 places it at the lower end of shortlists when it appears. A 15.3% positive visibility rate suggests AI systems mention Nurx in context but do not consistently frame it as a recommended choice for STD testing specifically.

The public interpretation: Nurx is recognized by AI systems but is not being advanced as a primary option, limiting its ability to capture AI-driven purchase decisions.

6. QuestDirect

QuestDirect holds a peripheral position in AI-driven discovery, with 11.3% presence and 4.7% recommendation coverage. Its rank-one rate is 1.0% and it appears in fewer than 3% of top-ten lists. A 6.0% positive visibility rate indicates limited favorable framing across platforms.

The public interpretation: QuestDirect is a minor presence in AI-generated STD testing recommendations and is not currently competing for shortlist leadership.

The Buying Moments That Now Decide the Category

Best STD Tests: Discovery and Evaluation

This cluster covers 301 observations across prompts including "at home STI test," "how to discreetly test for STD," "is there a rapid STD home test," and "STD test kit." These are the highest-intent moments in the category: consumers actively deciding which testing service to use, often without a specific brand in mind. AI responses to these prompts function as a direct purchase shortlist.

Within this cluster, Everlywell leads with 84 top-ten appearances and 74 top-three placements. myLAB Box follows with 73 top-ten and 63 top-three appearances. LetsGetChecked holds third with 69 top-ten and 62 top-three placements. These three brands dominate the recommendation lists AI systems generate for discovery-stage questions.

The conversion gap is clearest here. Labcorp OnDemand appears in 110 responses but only 26 top-ten lists. Nurx appears in 81 responses but only 30 top-ten lists. Both brands are surfaced by AI systems but consistently filtered out before the final shortlist is constructed. For a category where the AI response often ends the consideration phase, this distinction determines which brands receive inbound intent.

The full report tracks nine additional clusters across comparison, pricing, and decision-stage prompts. The public benchmark reflects discovery intent only.

Why Recommendation Power Is Concentrating

Recommendation power in AI systems reflects the depth and consistency of public evidence available for each brand. Everlywell, myLAB Box, and LetsGetChecked have built extensive source layers across review platforms, health comparison sites, editorial coverage, and official brand content. This gives AI systems multiple verifiable references to draw from when constructing a recommendation response.

The citation architecture matters because AI platforms do not recommend brands they cannot verify through public sources. A brand with strong official content, consistent review coverage, positive comparison-site mentions, and health-authority references is easier for an AI system to retrieve, evaluate, and advance confidently. Brands with thinner source layers, even if recognized by name, are more likely to appear in neutral mentions or contextual references rather than as ranked recommendations.

This creates a compounding dynamic. Brands that earn consistent recommendation credit appear more frequently in AI responses, which generates additional engagement, review content, and comparison coverage, which further strengthens their recommendation position. Brands outside this cycle face increasing difficulty breaking into AI-generated shortlists, regardless of their offline brand strength or marketing investment.

The Category's Most Visible Warning Sign

The most striking signal in this benchmark is the complete absence of STDcheck.com from AI-driven discovery. Despite being a recognizable brand in the STD testing category, STDcheck.com appears in zero of 301 observations across all six AI platforms tested. No presence. No mentions. No recommendations. No sentiment signals of any kind.

This is not a visibility problem in the conventional sense. AI systems are not retrieving STDcheck.com at all, meaning the brand does not exist within the consideration set that AI platforms are constructing for buyers. For a category where consumer discovery is increasingly AI-mediated, this level of absence represents a structural disadvantage that cannot be addressed through paid media or traditional brand awareness campaigns alone.

The brand's source architecture, its entity signals, content layer, citation presence, and public verification footprint, would need to be rebuilt before AI systems can discover, verify, and potentially recommend it. The longer this gap persists, the more durable the exclusion becomes as AI systems reinforce existing recommendation patterns.

What This Means for the Category

The STD testing category is experiencing shortlist compression. AI platforms are consolidating consumer choice around three brands, with the remaining seven competing for limited recommendation share. This pattern is unlikely to reverse on its own. As AI platforms become more embedded in health-related consumer decisions, the brands that hold top-three positions in these responses will capture a disproportionate share of discovery-driven demand.

Competitor displacement is already measurable. Nurx and Labcorp OnDemand, despite meaningful brand recognition and broad product availability, are being positioned as secondary options in AI-generated shortlists. Their presence in AI responses does not convert into recommendation credit, which means they are losing the moment of decision to brands with stronger source architecture. Without structural changes to how AI systems retrieve and evaluate these brands, the gap will continue to widen.

Trust-source dependency is the defining dynamic across this category. AI platforms recommend brands they can verify through multiple consistent public sources. Official content, review coverage, comparison-site presence, and health-authority references all contribute to the evidence layer that shapes recommendation eligibility. Brands that treat these source layers as secondary marketing considerations will continue to underperform in AI discovery, regardless of their clinical quality or pricing competitiveness.

AI discovery is now part of the buyer journey for STD testing. The consumers asking "which at-home STD test should I use" are receiving a direct answer from an AI system before they visit any brand website. The brands that appear in those answers, and the positions they hold, are increasingly determinative of where demand flows. Brands outside the top three shortlist positions need stronger entity, content, source, and citation architecture to remain relevant in this environment.

What This Public Benchmark Does Not Include

This public version does not include:

• Full cluster dataset across all 10 buyer-stage clusters
• Prompt-level response tables showing exact AI outputs
• Citation-source failure maps identifying which sources are missing or weak
• Platform-by-platform recovery priorities across all six AI systems
• Entity and schema diagnostics
• Source-layer gap analysis
• Company-specific content recommendations
• Exact competitor threat profiles
• Full paid opportunity model

This page shows the market shape. The paid report shows the repair map.

Methodology and Disclaimers

1. Market studied: STD testing services, including at-home test kits, lab-based testing, and related diagnostic services.
2. Brands and entities included: Everlywell, myLAB Box, LetsGetChecked, Nurx, Labcorp OnDemand, QuestDirect, Priority STD Testing, PlushCare, STDcheck.com, and Health Testing Centers. This universe may not include all market participants.
3. Data collection period: August 2026, with extraction on August 1, 2026.
4. AI platforms tested: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, and Perplexity.
5. Observations analyzed: 301 observations analyzed across 800 total prompts, including 618 unique questions and 799 brand-mentioned prompts. Prompt count at the individual level was not separately disclosed.
6. Prompt categories: Discovery and evaluation prompts, including "best STD test," "at home STI test," "how to test for STD," and related consideration-stage queries. Comparison, pricing, and decision-stage clusters are covered in the full report and are not reflected in this public benchmark.
7. Definition of a mention: A mention means the company appeared in an AI-generated response, regardless of sentiment or recommendation status.
8. Definition of a valid recommendation: A valid recommendation is a positive, shortlist-quality or ranked recommendation that earns recommendation credit. Visibility and recommendation credit are distinct metrics. Appearing in a response does not constitute a recommendation.
9. Metrics used: Valid recommendation coverage, top-three rate, rank-one rate, top-ten rate, average recommended rank, positive visibility rate, neutral visibility rate, negative visibility rate, and net sentiment score. Monetary opportunity metrics from the source data are omitted from this public benchmark.
10. Limitations: This is a point-in-time benchmark. AI outputs change based on model updates, source availability, and platform-level changes. This report is not a full audit or complete market census. Results reflect the specific prompts and platforms tested during the collection window.

Next Steps

For a company-specific Authority Index report, the deeper analysis would show which prompts each company wins or loses, which AI platforms are under-recognizing the brand, which source layers are shaping recommendations, and what changes may improve AI shortlist eligibility.